ICYMI, some of this week’s featured content includes FDA warnings about JAK inhibitors, and articles about laser treatment for lentigines, Image-Guided Superficial Radiotherapy for BCC and SCC, the risk of insomnia in vitiligo patients, plus more.
Dermavant has announced it has dosed the first patient in its phase 3 trial evaluating tapinarof cream for the treatment of moderate to severe atopic dermatitis.
Although JAK inhibitors have shown efficacy in treating challenging conditions, federal regulators continue their safety reviews.
A recent study delved into how well the 730 nm picosecond-domain laser could treat facial and non-facial lentigines in patients.
New study data shows positive data for Image-Guided Superficial Radiotherapy (IGSRT) in treating basal cell carcinoma and squamous cell carcinoma.
A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.
The drop in use was starkest in the northeast.
The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.
The organization is also calling on everyone to be vaccinated against the disease.
The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.
Derm-Biome’s topical compounds have positive results in preclinical trial.
Jill Waibel, MD, discusses her recommendations on how to treat keloids and scaring using lasers in her presentation at the Skin of Color Update 2021.
The National Rosacea Society has recently released recommendations based on a group discussion regarding updates in rosacea.